cancer, technology, chemotherapy

Introduction: Chimeric Antigen Receptor (CAR) T-cell therapy is advancing cancer treatment with a personalized approach that reprograms a patient’s own immune cells to target and kill cancer cells. Originally developed for hematologic malignancies, CAR-T therapy has shown strong promise in treating otherwise difficult cancers. This therapy presents a unique opportunity for the development of novel oncological and immunotherapy drugs. T-cells are harvested from a patient’s blood sample, and a viral or non-viral vector is used to introduce the genetic instructions to create the CAR. The vector is a delivery system that introduces the CAR gene, enabling the cell to produce these specific receptors. After these trained cells multiply, they are reintroduced into the patient and multiply in the bloodstream. These cells are now able to detect cancer cells that have hidden from standard immune identification. Development: CAR-T therapy has evolved from a long lineage of immunotherapy milestones—from 19th-century bacterial-based approaches such as Coley’s Toxins and BCG vaccine studies to modern…